Hélène Aschmann, PhD, joined the Epidemiology, Biostatistics and Prevention Institute in April 2016 and defended her PhD thesis in May 2020. Her thesis focused on informing patient-centered care for people with multiple chronic conditions. To this purpose, she models the balance of benefits and harms of different interventions and considers patients’ values and preferences.
Since the start of the Sars-CoV-2 epidemic, Dr. Aschmann acted as one of the main investigators of the Zurich Sars-CoV-2 Cohort study and lead the recruitment of the study [https://ebpi.uzh.ch/en/translational_research/community_and_health/zurich_coronavirus_cohort.html]. Her research focuses on the burden and efficacy of quarantine for close contacts of infected persons. As a collaboration between the EBPI and the cantonal Department of Health (Gesundheitsdirektion Zürich), Dr. Aschmann also lead the data analysis of contact tracing data from July 2020 to Feburary 2021.
In April 2021, Dr. Aschmann started her SNSF early postdoc.mobility fellowship to continue developing methods for benefit-harm assessments. In her fellowship at the University of California, San Francisco (https://profiles.ucsf.edu/helene.aschmann), she examines who should receive preventive treatment for latent tuberculosis.
Meanwhile, Dr. Aschmann continues to support the Zurich Sars-CoV-2 Cohort study for the EBPI.

Please see my Linkedin profile: Linkedin

• Benefit-harm assessments to inform patient-centered care for older people with multiple chronic conditions
• PCORI: Benefit harm assessment methods for guidelines